Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Star Lake Bioscience Co., Inc. operates in the biotechnology sector, focusing on the development and commercialization of innovative therapeutics in China. With a market cap of $7.6B and a revenue of $15.9B, the company has a competitive edge through its proprietary drug development platform and strategic partnerships with leading research institutions in Guangdong.
Star Lake generates revenue primarily through the sale of its proprietary therapeutics, which include treatments for chronic diseases and oncology. The company benefits from strong pricing power due to its unique formulations and established market presence, complemented by revenue from research collaborations and licensing agreements that leverage its R&D capabilities.
Regulatory approvals for new drug candidates
Partnership announcements with global pharmaceutical companies
Clinical trial results impacting product pipeline
Market expansion into new therapeutic areas
Regulatory changes affecting drug approval processes
Technological disruption in drug development methodologies
Emergence of generic competitors
Increased R&D spending by larger pharmaceutical companies
High capital expenditure requirements impacting liquidity
Potential for increased debt levels if cash flow does not improve
moderate - the biotechnology sector is somewhat insulated from economic downturns, but funding for R&D can be affected by overall economic conditions.
Interest rates impact financing costs for R&D and can influence the valuation multiples applied to biotech firms, particularly those with high capital requirements.
minimal - the company has a manageable debt/equity ratio of 0.67, indicating limited reliance on external credit.
growth - the company is positioned for significant growth driven by its innovative drug pipeline and market expansion.
high - historical volatility is elevated due to the binary nature of clinical trial outcomes and regulatory approvals.
